Appian and PSI CRO Collaborate on AI Solutions for Clinical Trials

A Strategic Collaboration between Appian and PSI CRO

In a groundbreaking move to revolutionize clinical trial operations, Appian (Nasdaq: APPN) and PSI CRO have announced their first collaborative effort: an AI-powered process orchestration solution. This innovative offering aims to streamline the identification and selection of clinical trial sites, addressing various therapeutic areas, indications, and geographical considerations.

The collaboration marks an essential step for PSI, a well-established Contract Research Organization (CRO) known for its exceptional patient enrollment rate across multiple therapeutic fields. As a global leader in clinical research, PSI's partnership with Appian is set to bring transformative advantages to the clinical trial lifecycle.

Enhancing Efficiency and Transparency

The newly launched AI solution signifies the beginning of a wider strategy aimed at integrating automation and AI capabilities into the clinical trial process. Recognized as a leader in the 2026 Gartner® Magic Quadrant™ for Business Orchestration and Automation Technologies (BOAT), Appian’s platform is identified as the backbone of this solution. The tool is designed to provide enhanced visibility and facilitate quicker decision-making throughout the site selection procedure.

The complexity of clinical trial site selection is intensified by the need for coordination among diverse stakeholders, extensive documentation, and parallel activities spanning multiple countries. By digitizing these previously manual, decentralized processes, the new solution aims to enhance operational efficiency, transparency, and speed throughout clinical trials. This integration is expected to significantly reduce the time taken for each step, from project initiation to site selection.

The AI-Powered Transformation

One of the most significant advancements presented by this solution is its capability to orchestrate not just basic tasks but the entire end-to-end process. It effectively connects personnel, data, systems, and AI within a unified workflow, which enhances coordination across teams and regions. Additionally, it automates information and document processing, manages routing, and offers real-time insights into process performance.

This integrated approach serves to create a scalable foundation for faster outcomes and improved consistency in clinical trials. According to Kirill Soldatov, Head of Process Improvement at PSI, this AI-centric solution aligns with PSI's commitment to delivering timely and efficient clinical trials. By enhancing operational connectivity through advanced automation and process orchestration, PSI aims to significantly diminish non-enrolling sites and the delays often associated with patient enrollment.

Future Prospects

This project is not merely a singular achievement; it represents a significant platform strategy for both PSI and Appian, wherein automation and AI are intertwined within standard operational workflows. Looking forward, both companies are poised to examine additional use cases, extending AI-driven process orchestration throughout the entire clinical trial lifecycle.

The potential benefits of this collaboration extend beyond mere efficiency gains. With the aim of reducing clinical study durations and enhancing predictability, the ultimate goal is to facilitate the swift introduction of novel products to market while driving down costs for consumers.

As life sciences organizations continue to face increased demands for faster time-to-market, leveraging such AI-driven innovations becomes crucial. This partnership between Appian and PSI CRO serves as a pivotal model for how technology can reshape the operations of clinical studies, ultimately leading to improved healthcare outcomes and innovation in the medical field.

For further insights into how AI automation can expedite the pathway to market for life sciences companies, be sure to explore the solutions provided by Appian and PSI CRO. The future of clinical trials is here, and it's powered by AI.